Call for implementation of NICE guidance on CardioQ-ODM

23 January 2012

Deltex Medical Group plc, a developer of oesophageal Doppler monitoring (ODM), has commented on the report on standards of surgical care in the NHS by the UK National Confidential Enquiry into Patient Outcome and Death (NCEPOD).

The report addresses a number of deficiencies in care commonly experienced by high-risk surgical patients and makes recommendations to improve fluid management before, during and after surgery.

The report calls specifically for the implementation of the NICE Medical Technology Guidance that recommended CardioQ-ODM in NHS patients undergoing major or high-risk surgery and in high-risk patients undergoing lower risk surgery:

“Better intra-operative monitoring for high risk patients is required. The evidence base supports the use of peri-operative optimisation and this relies on extended haemodynamic monitoring. NICE Medical Technology Guidance 31 relating to cardiac output monitoring should be applied.”

CardioQ-ODM is the cardiac output monitoring technology recommended by NICE in its guidance of 30 March 2011.

Ewan Phillips, Deltex Medical’s Chief Executive, commented: "NCEPOD’s recommendation that the NICE guidance on CardioQ-ODM be implemented provides powerful clinical backing to the accelerated adoption of our products in the NHS. It follows the announcement on Monday that the NHS has decided to launch a national drive to get full implementation of fluid management during surgery into practice across the NHS.”

Reference

1. National institute for Health and Clinical Excellence. Medical Technology Guidance 3. CardioQ-ODM (oesophageal Doppler monitor) 2011. www.nice.org.uk/guidance/MTG3